

Pioneering trusted medical solutions to improve the lives we touch

Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence care and infusion care.

- > Total revenues of \$2,073 billion in 2022
- > Chronic care market of \$14bn growing at 4-8% pa
- > Leading positions across key categories



Scan this QR code to visit www.convatecgroup.com



Advanced Wound Care

Advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns



Ostomy Care

Devices, accessories and services for people with a stoma, commonly resulting from causes such as colorectal cancer, inflammatory bowel disease and bladder cancer



Continence Care

Products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes



Infusion Care

Disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as Parkinson's disease

Chronic care is a large and growing market


We are focused on the chronic care market:

>90%

of our revenues are from serving chronic care patients. These revenues are often recurring in nature as patients rely on our solutions

1. An ageing global population

Global population aged 60+



Source: United Nations, World Population Prospects

2. Chronic conditions are rising

Approximately one in three adults globally suffer from multiple chronic conditions (e.g. diabetes, cancer).

Source: The global burden of multiple chronic conditions, Cothar Hajat and Emma Stein

3. People are now living longer

Average life expectancy in the world (years)



Source: United Nations Population Divisions estimates

We have leading positions

	Market size	Market growth	Market position
AWC	\$7.0bn	~5%	#2 globally
OC	\$3.0bn	~4%	#3 globally
CC	\$2.0+bn	~4%	#1 in the US
IC	\$1.6bn	~8%	#1 globally

Pivoting to sustainable and profitable growth - executing our FISBE strategy



Focus on strengthening customer loyalty in key markets and categories



Innovate to increase vitality and velocity of trusted medical solutions



Simplify to improve productivity across our organisation




Build and embed mission-critical capabilities and winning culture




Execute with excellence while integrating ESG

Organic sales growth



Adjusted operating profit growth



Medium term targets

Organic revenue growth	4-6% pa
Expanding adj. operating profit margin	Mid 20s over time

Double-digit earnings per share & free cash flow CAGR

Our ESG framework: Convatec Cares

Customers

Delivering for our customers

Colleagues

Enabling our people to thrive

Commerce

Behaving ethically and transparently

Communities

Protecting the planet and supporting communities

Experienced leadership



Dr John McAdam CBE - Chair

Chairman since September 2019, 25 years experience on FTSE/PLC boards as non-executive Chairman/Director, including Sara Lee, Rolls Royce, Rentokill & J Sainsbury.



Karim Bitar - CEO

CEO since September 2019. Previously, CEO of Genus for 8 years. Prior to that, spent 15 years with Eli Lilly & Co. and 4 years as a non-executive Director of Spectris Plc.



Jonny Mason - CFO

CFO since January 2022. Previously CFO of Currys Plc between 2018-2021. Prior CFO experience at Halfords PLC, Scandi Standard AB and Odeon & UCI Cinemas.